Best Compounded Tirzepatide in 2026: 8 Pharmacies Still Legal After the Shortage

← Best Tirzepatide Online (full ranking) · Tirzepatide hub · GLP-1 hub

The FDA declared the tirzepatide shortage resolved on December 19, 2024. Most best-of lists you will find today were written before that, and they are quietly wrong.

If you have been trying to figure out whether compounded tirzepatide is still legal, safe, and worth it, the mixed signals are real. This guide ranks nine providers still legitimately dispensing best compounded tirzepatide in April 2026 under the narrow 503A pathway that replaced the shortage exemption.

Two dates matter. The FDA declaratory order resolved the shortage on December 19, 2024. 503A enforcement discretion ended February 18, 2025, and 503B outsourcing facilities followed March 19, 2025. Compounding because it is cheaper than Zepbound is now prohibited as “essentially a copy.” Compounding for a documented individual medical need is still legal.

Three pathways qualify. A documented polysorbate 80 allergy (an excipient in Mounjaro and Zepbound). A dose or route not commercially available (microdose below 2.5 mg, oral or sublingual). A combination formulation with a clinically significant difference (tirzepatide plus niacinamide, B6, or glycine and B12).

Still deciding between a telehealth provider and a specific pharmacy? Start with our best online tirzepatide provider guide. This article goes deeper on the pharmacy side.

We ranked on four criteria. Legal fit for 2026 (a legitimate 503A pathway or named 503B partner). Pharmacy accreditation (PCAB, NABP, or ACHC, verifiable at achc.org/find-a-provider/ and nabp.pharmacy). Pricing transparency at maintenance dose (10 mg weekly, not starter). Real clinical oversight, not a 60-second questionnaire.

This guide is for US-based self-pay adults, often already on compounded tirzepatide and shopping a more compliant provider. Not for patients with complex comorbidities who need in-person management.

Peak Wellness leads on price transparency and named pharmacy access. Eden leads on accreditation. Empower and Strive lead on personalization formulations. MEDVi leads on clinical rigor. CoreAge RX leads on price. We also name two to skip.

1. Peak Wellness: Flat-Rate Pricing With a Named 503A Pharmacy

Peak Wellness charges $229 for your first month and $349 per month flat after that, regardless of dose. That price stays the same whether you are on 2.5 mg or 15 mg. No membership fee, no dose-based escalation, no hidden consultation charges.

Legal fit (2026 ranking lens)

Peak Wellness routes prescriptions through Epiq Scripts, a named 503A pharmacy that is PCAB-accredited, URAC-certified, LegitScript-certified, and FDA-registered with no public warning letters as of April 2026. Licensed in 45 states plus Puerto Rico and DC. The intake questionnaire screens for documented medical need (polysorbate 80 allergy, non-commercial dose, or route) before the prescription routes to Epiq Scripts. Provider-side screening is built into the flow.

Pricing

• First month: $229 (new-patient discount)
• Ongoing: $349/month flat, all doses through 15 mg
• No membership fee
• HSA and FSA eligible

Specs

Sub-four-hour physician review. Ships within 48 to 72 hours of approval. All-inclusive: medication, physician oversight, injection supplies, expedited shipping, patient portal. Available in all 50 states. Trustpilot 4.6 out of 5.

Pros

• Named 503A pharmacy (Epiq Scripts) with PCAB, URAC, and LegitScript credentials
• Flat-rate pricing through 15 mg, no dose-based escalation
• Fastest documented approval-to-ship time on this list
• All 50 states, no coverage gaps
• No membership fee

Cons

• Newer platform than Eden, Mochi, or Henry Meds, less accumulated review volume
• Does not accept insurance (true of all compounded GLP-1 providers)
• No bundled coaching or dietitian support
• Injectable only, no oral or sublingual formats

Best for: Readers who want flat-rate pricing, a named and verifiable pharmacy partner, and the fastest path to a 503A-filled prescription.

Skip if: You need oral or sublingual formats (Henry Meds or Shed), want bundled coaching (Mochi), or need the strongest accreditation stack (Eden’s triple accreditation edges out).

2. Eden: Triple-Accredited and Vertically Integrated

Eden is the only compounded tirzepatide provider we reviewed that owns its compounding pharmacy. That changes the quality-control math.

Eden routes prescriptions to its in-house 503A pharmacy, Contigo Compounding, which it acquired in August 2025. Vertical integration removes the weakest link in most compounded tirzepatide deliveries: the handoff between a telehealth marketing brand and a third-party pharmacy. That handoff is exactly where the Aequita contamination scandal happened in 2025 (more under Mochi). When brand and pharmacy are one organization, the incentive to cut corners on cold-chain logistics, glassware, or technician credentialing disappears.

Legal fit (2026 ranking lens)

Eden carries triple accreditation: NABP (verify at nabp.pharmacy), PCAB, and ACHC (verify at achc.org/find-a-provider/ using the PCAB Sterile Compounding filter). Third-party FDA/DEA-registered lab testing runs on every compounded lot, including potency, sterility, and endotoxin assays. No FDA warning letters or active manufacturer litigation as of April 2026. This is the most independently verifiable provider in the category.

The caveat: Eden does not publicly market combination formulations like tirzepatide plus niacinamide or B6. Their legal argument rests on patient-specific dose personalization and legitimate 503A state licensure, which is narrower than Empower’s combination-formulation pathway.

Pricing

• First month: $249 (starter dose, typically 2.5 mg)
• Ongoing: $349/month flat, all doses through 15 mg
• Maintenance (10 mg weekly): $349/month
• Brand-name Zepbound via Eden: $1,399 to $1,695/month (not our pick at that price)

Specs

Flat pricing through dose escalation. No membership fee. 24/7 unlimited messaging with a dedicated care team. Free shipping. Same-day async consultation for the initial visit. Quarterly check-ins with a licensed clinician to maintain refills. Every lot tested by a third-party FDA/DEA-registered lab for potency, sterility, and endotoxin before release. Certificate of Analysis on request.

Pros

• Triple accreditation (NABP, PCAB, ACHC), independently verifiable
• In-house 503A pharmacy (Contigo), tightest supply-chain control in the category
• Flat pricing through the 15 mg dose
• No membership fee

Cons

• Not available in all 50 states for compounded formulations
• No explicit combination formulations (niacinamide, B6, glycine) for readers who need that pathway
• Brand-name Zepbound option priced well above LillyDirect ($1,399+ vs $449)

Best for: Readers who want the most independently verifiable supply chain and qualify under the state-licensed 503A patient-specific pathway, or simply want a provider that owns its pharmacy.

Skip if: You need a named combination formulation (tirzepatide plus niacinamide or plus B6) to anchor your personalization rationale. Empower or Strive fit better.

3. Empower Pharmacy: The Tirzepatide + Niacinamide Personalization Pathway

Most telehealth brands will not answer this: on what specific legal basis do you still compound tirzepatide in 2026? Empower Pharmacy is one of the rare providers that has published its answer.

Empower is a Houston-based PCAB-accredited compounding pharmacy operating both 503A and 503B facilities. Prescribers across the country refer patients for compounded tirzepatide plus niacinamide (17 mg/mL tirzepatide, 2 mg/mL niacinamide in 4 mL vials) and tirzepatide plus B6 (50 mg/mL pyridoxine hydrochloride, 5 to 30 mg B6 per injection). The formulation is the legal argument: Mounjaro and Zepbound do not contain niacinamide or B6, so a compounded product with those additives is arguably not “essentially a copy.”

Legal fit (2026 ranking lens)

Empower’s official post-shortage guidance states that a combination formulation “may be considered clinically different because the commercial product does not contain those additional ingredients.” That written position is rare. Most telehealth brands do not publish their legal rationale at all. Whether the FDA will ultimately agree is unresolved, but Empower is documenting its argument in writing.

The April 2025 FDA warning letter, named

On April 2, 2025, the FDA cited Empower for unsanitary conditions at its Houston 503B facility, including a pyridoxine HCL batch released despite microbial contamination. The warning letter targeted the 503B site, not the 503A operation. Eli Lilly also sued Empower (case 2:25-cv-02183, refiled Texas July 2025).

This is not a provider you pick if you want zero regulatory noise. You pick Empower because the 503A personalization pathway is the cleanest legal argument in the category and the niacinamide and B6 formulations do not exist from brand-name.

Pricing

• Starter dose (2.5 mg): $200 to $300/month through partnered telehealth providers
• Maintenance (10 mg weekly): typically $250 to $400/month
• Combination formulations add roughly $10 to $20/month over base tirzepatide
• Prices vary because Empower is the pharmacy, not the front-end brand

Pros

• Explicit 503A personalization pathway published in writing
• Named combination formulations with documented concentrations (tirzepatide plus niacinamide, tirzepatide plus B6)
• PCAB-accredited
• Operating both 503A and 503B facilities (with caveats)

Cons

• April 2025 FDA warning letter at the 503B Houston facility
• Active Eli Lilly litigation refiled in Texas (July 2025)
• Combination formulations lack human RCT evidence against tirzepatide alone
• Pricing transparency depends on the prescribing provider you route through

Quick comparison vs Eden: Eden is the accreditation-first pick. Empower is the legal-pathway-first pick. Pick Empower if your prescriber is recommending a combination formulation. Pick Eden if you want one clean vertical-stack relationship.

4. Strive Pharmacy: Tirzepatide Plus Glycine and B12

Patients over 40 who lose 20% of their body weight on tirzepatide often lose meaningful muscle with it. Strive Pharmacy’s formulation is one of the few that addresses that directly.

Strive is a 503A compounding pharmacy that partners with prescribers across the country. Their flagship GLP-1 product is tirzepatide combined with glycine and B12 (cyanocobalamin). Glycine supports muscle preservation during rapid weight loss and stabilizes the tirzepatide molecule. B12 supports energy and may reduce nausea during titration.

Legal fit (2026 ranking lens)

Eli Lilly sued Strive in Delaware federal court in 2025. The court dismissed the case in October 2025 for lack of personal jurisdiction. Lilly refiled in Arizona, ongoing as of April 2026. The dismissal was procedural, not a ruling on the personalization merits, but it allowed Strive CMO Zachary Shurtleff to publicly commit to continued patient access.

Like Empower, Strive’s legal position rests on the combination-formulation argument. Glycine and B12 are not in Mounjaro or Zepbound.

Pricing

• Starting package: $100 through Strive’s direct portal
• Per-dose pricing not publicly listed on the product page
• Find the prescriber at strivepharmacy.com/find-a-provider
• Typical all-in monthly cost at maintenance: $200 to $350 depending on the telehealth prescriber

Specs

Tirzepatide plus glycine plus B12, standard 503A formulation. Glycine rationale: muscle preservation during weight loss and molecular stabilization. B12 rationale: nausea reduction during titration. No FDA-registered bulk supplier issues flagged in our research.

Pros

• Combination formulation (glycine plus B12) with documented clinical rationale for muscle preservation
• Lilly case dismissed in Delaware (October 2025), one of the few pharmacies to win a procedural round
• CMO publicly committed to ongoing patient access
• Find-a-provider portal makes it easier to locate a prescribing clinician

Cons

• States served not publicly specified on product page
• No NABP or PCAB accreditation listed on the product page (verify separately via nabp.pharmacy)
• Active Lilly litigation refiled in Arizona
• Combination formulation evidence is plausible but not RCT-validated against tirzepatide alone

Best for: Readers whose clinical rationale includes muscle preservation (often patients over 45 doing aggressive weight loss) or nausea management via B12.

Skip if: You want prominent accreditation badges on the landing page. Strive’s product page does not list NABP or PCAB status, which some readers will reasonably treat as a red flag. Verify via nabp.pharmacy before ordering.

5. MEDVi: Video Consultations and Named Partner Pharmacies

Most compounded tirzepatide telehealth brands put you through a five-minute questionnaire and call that a medical evaluation. MEDVi requires a real video consultation with a licensed clinician, and names its partner pharmacy in writing.

MEDVi routes prescriptions to Belmar Pharma Solutions, a network of six 503A facilities across Colorado and Florida. Belmar ships to all 50 states plus DC, Puerto Rico, and Guam. Most telehealth providers (Henry Meds, Mochi) do not publicly identify their compounding partners, so the named-pharmacy transparency is unusual.

Legal fit (2026 ranking lens)

MEDVi operates through 503A compounding. The named pharmacy (Belmar) is the verifiable anchor. You can look up Belmar on state pharmacy boards and NABP, which you cannot do when the partner is undisclosed. The required video consultation also creates a clearer paper trail for “documented medical need” than an async questionnaire.

Important caveat: MEDVi received an FDA warning letter on February 20, 2026 for false or misleading marketing claims about compounded semaglutide and tirzepatide. This was a marketing issue, not a pharmacy-quality issue. Check whether MEDVi’s current marketing has been updated before purchase.

Pricing

• First month: $279 (starter dose, 2.5 mg)
• Maintenance (10 mg weekly): $399 to $499/month depending on plan tier
• HSA/FSA eligible for both consultation and medication

Specs

Video consultations required. Quest Diagnostics lab work included when clinically necessary. LegitScript certified. 4.4 to 4.5 Trustpilot from 4,000+ reviews. Serves 49 states (all except North Dakota). 24/7 human support. A few states (KS, IN, MS, NM, OK, WV) require an in-person visit before a first prescription.

Pros

• Real video consultation with a licensed clinician, not an async form
• Partner pharmacy named publicly (Belmar Pharma, six 503A facilities)
• Quest Diagnostics labs included when clinically justified
• 49-state coverage
• HSA/FSA approved

Cons

• February 2026 FDA warning letter for marketing claims, recent and material
• Premium pricing at $399 to $499/month maintenance (higher than Mochi, Henry Meds, CoreAge RX)
• Video-required workflow is a barrier for readers who wanted async
• Some states require an in-person visit

The verdict: If your priority is the most legally defensible paper trail (real clinical evaluation, named pharmacy, documented personalization), MEDVi is the pick. Read their current marketing carefully given the February 2026 warning letter.

6. Henry Meds: Oral and Sublingual Options with No Membership

Some patients cannot bring themselves to self-inject weekly. For them, Henry Meds is one of the few providers still offering oral and sublingual tirzepatide formulations.

Henry Meds is a cash-pay telehealth provider offering compounded tirzepatide in injectable, oral, and sublingual formats. No membership fee. Asynchronous consultation, no video. 41 US states plus DC.

Legal fit (2026 ranking lens)

Oral and sublingual tirzepatide are routes not available from Mounjaro or Zepbound (both subcutaneous injection only). Under the 503A personalization pathway, “a dose or route not commercially available” is one of the three named legal justifications for compounding. That gives Henry Meds’ oral and sublingual line a distinct legal footing the injectable line does not have.

Important caveat: Eli Lilly has active litigation against Henry Meds (case 3:25-cv-0353, filed April 2025). Holland & Knight analysis notes Lilly’s theory is that pill and drop forms were never studied by the FDA for tirzepatide and cannot be marketed as “personalized” if mass-produced. If Lilly prevails, the oral and sublingual program is the most legally exposed in this list.

Pricing

• Starter dose (2.5 mg): $199/month
• Maintenance (10 mg weekly): escalates with dose, budget $299 to $399/month
• No membership fee
• HSA/FSA eligible with valid prescription

Specs

Starts at $199/month for injectable tirzepatide. Oral and sublingual options priced in a similar range. Cash-pay only, no insurance billing. 4.5/5 Trustpilot from 12,000+ reviews, one of the largest volumes in the category. Not available in AL, AK, AR, HI, LA, MS, MO, SC, WV.

Pros

• Oral and sublingual formats (route-of-administration personalization pathway)
• No membership fee, fits “no membership” keyword intent directly
• 12,000+ Trustpilot reviews (largest volume in category)
• Asynchronous model (faster intake than MEDVi)

Cons

• Not available in 9 states
• Active Eli Lilly litigation, oral/sublingual program is the most legally exposed
• Price increases with dose escalation (not flat-rate)
• No lifestyle coaching or dietitian support
• Partner pharmacy not publicly named

Direct recommendation: If you want no membership and either cannot inject or have a prescriber endorsing oral or sublingual, start with Henry Meds. For injectable only, Eden and Mochi offer cleaner flat-rate pricing and better pharmacy transparency.

7. Mochi Health: Flat $199 Medication Cost with Obesity-Medicine Physicians

Mochi Health had the worst compounded tirzepatide supply-chain scandal of 2025. A year later, they still have the best flat-rate pricing at the 15 mg dose. Both things are true.

Mochi is a telehealth provider with board-certified obesity-medicine physicians and flat $199/month medication pricing across all tirzepatide doses (2.2 mg through 16.6 mg weekly). Membership is $79/month. All-in: $278/month. All 50 states.

Legal fit (2026 ranking lens)

Mochi operates through 503A compounding. After the February 2025 Aequita Pharmacy shutdown, Mochi changed compounding partners. The current partners are not publicly disclosed, a transparency gap relative to MEDVi. Eli Lilly’s lawsuit against Mochi was dismissed without prejudice on August 28, 2025. The court found Lilly “failed to plausibly allege an injury in fact.” Lilly can refile.

The Aequita context, addressed directly

In February and March 2025, Washington State issued a Notice of Immediate Jeopardy to Aequita Pharmacy (Mochi’s then-partner) for unlicensed day laborers recruited from Home Depot and Lowe’s parking lots, cheap Alibaba glassware that shattered in transit, and visible contamination in vials. The FDA recalled 2,000+ Aequita vials on July 18, 2025 for “lack of processing controls.” Mochi’s clients posted photos of floating contamination before the regulatory action.

Mochi changed partner pharmacies after the shutdown but has not publicly named the replacements. Weigh that against current pricing and clinical credentialing.

Pricing

• Membership: $79/month (mandatory)
• Medication: $199/month, flat across all doses
• All-in: $278/month at any dose
• Starter and maintenance are the same price (unusual in the category)

Specs

Best flat-rate pricing at the top end of the dose range. At 15 mg, competitors escalate to $449+. Mochi stays at $278 all-in. Board-certified obesity-medicine physicians. 4.4/5 Trustpilot from 15,600+ reviews. LegitScript certified. All 50 states.

Pros

• Best flat-rate pricing at 12.5 mg and 15 mg
• Board-certified obesity-medicine physicians
• 15,600+ Trustpilot reviews
• All 50 states
• Lilly lawsuit dismissed as of April 2026 (subject to refile)

Cons

• Aequita partnership history (February to July 2025 contamination, unlicensed workers, recalls)
• Current partner pharmacies not publicly named
• Mandatory $79/month membership on top of medication cost, does not fit “no membership” searches
• Dismissed Lilly suit can be refiled

Best for: Readers maintaining at 12.5 mg or 15 mg who want the lowest all-in cost with obesity-medicine clinical oversight and are comfortable that Mochi has changed pharmacies since Aequita.

Skip if: You want the partner pharmacy named (choose MEDVi) or want no-membership pricing (choose Eden or Henry Meds).

8. CoreAge RX: Cheapest Flat-Rate Option at $149 Per Month

At $149/month flat across every dose, CoreAge RX is the cheapest legitimate compounded tirzepatide provider we found in 2026. The trade-off is transparency.

CoreAge RX is a telehealth provider based in Wichita Falls, Texas, offering compounded tirzepatide at a flat $149/month across all doses, the lowest flat-rate price in our review. LegitScript certified. Temperature-controlled packaging. Board-certified physician review claimed. Nationwide availability claimed.

Legal fit (2026 ranking lens)

The honest caveat: CoreAge RX does not publicly disclose whether its partner pharmacy is 503A or 503B, nor does it publish the pharmacy name. The site does not list PCAB, NABP, or ACHC accreditation on the product page. For a “documented medical need” 503A pathway, the patient-specific rationale sits on the prescribing clinician. The provider’s public-facing transparency is thinner than Eden, Empower, Strive, MEDVi, or Mochi.

One competitor press release (Kinross Research) named CoreAge RX “Best Overall” in an award-style rubric, but that rubric did not weigh pharmacy accreditation. Ours does.

Pricing

• All doses: $149/month flat
• Starter and maintenance identical
• No membership fee
• FSA/HSA accepted

Specs

Compounded tirzepatide at $149/month flat across all doses. LegitScript certified. FSA/HSA accepted. Temperature-controlled packaging. Board-certified physician review. Nationwide availability claimed.

Pros

• Lowest flat-rate price in the review at $149/month
• Flat pricing through 15 mg dose
• FSA/HSA accepted
• LegitScript certified

Cons

• Partner pharmacy not named publicly, material transparency gap
• No specific 503A or 503B designation confirmed in public materials
• No NABP or PCAB accreditation listed on the product page
• No established review volume to triangulate quality
• No membership fee also means no coaching or dietitian support

Quick comparison vs Mochi: CoreAge RX is $129/month cheaper than Mochi at 15 mg maintenance. The savings are real. So is the reduced transparency. If accreditation and named-partner transparency matter, pay the Mochi or Eden premium. If you have an experienced prescriber you trust and just need the medication at the lowest flat rate, CoreAge RX is the honest cheapest pick.

9. Shed: Weight Loss Guarantee and Multiple Delivery Formats

Shed is the only provider in this list that will refund your money if you lose less than 10% of your body weight, provided you stick to the protocol.

Shed (also known as ShedRx) is a telehealth provider offering compounded tirzepatide in four delivery formats: injections, drops, lozenges, and tablets. No membership fee. Serves roughly 40 states. The headline feature is the 10% weight loss guarantee. If a patient follows the protocol and loses less than 10% of body weight, Shed refunds the medication cost.

Shed takes the route-of-administration approach to the 503A personalization pathway. For a fuller view of telehealth providers, see our best online tirzepatide guide, which covers provider-side decisions this article treats as secondary to the pharmacy question.

Legal fit (2026 ranking lens)

Drops, lozenges, and tablets are routes of administration not commercially available from Mounjaro or Zepbound. That is the same 503A personalization pathway Henry Meds’ oral line uses. Shed’s pharmacy partner is not publicly named on the product page, a transparency gap.

Pricing

• Lower doses (2.5 mg, 5 mg): $299/month
• Higher doses (7.5 mg and up): $399/month
• Price escalates with dose (not flat-rate)
• 10% weight loss guarantee with adherence documentation
• Two-month minimum commitment

Specs

Four formats (injections, drops, lozenges, tablets). 4.6/5 Trustpilot from 613 reviews, smaller volume than Henry Meds or Mochi but the average is strong. No membership fee. Roughly 40 states served.

Pros

• 10% weight loss guarantee (unique in the category)
• Four delivery formats
• No membership fee
• 4.6/5 Trustpilot

Cons

• Two-month minimum commitment
• Price increases with dose escalation
• Reports of missed shipments and delayed customer support responses
• Pharmacy partner not publicly named
• Approximately 40-state coverage (narrower than Mochi or MEDVi)

Best for: First-time users who want a financial safety net, or readers who want a non-injection format with a different provider than Henry Meds.

Skip if: You are already on maintenance dose (no guarantee benefit for dose-switchers) or need coverage in a state Shed does not serve.

The Bottom Line

Picking a compounded tirzepatide provider in April 2026 comes down to one question: on what legal basis are you still compounding this? Nine have a real answer. Two do not.

Pick by reader type

• Flat-rate pricing with a named, verifiable 503A pharmacy: Peak Wellness.
• Most independently verifiable supply chain: Eden.
• Prescriber recommending a combination formulation (niacinamide or B6): Empower Pharmacy.
• Muscle preservation priority or glycine plus B12 rationale: Strive Pharmacy.
• Real video consultation and a named partner pharmacy: MEDVi (with the February 2026 marketing warning letter in mind).
• No membership and oral or sublingual options: Henry Meds.
• Maintaining at 12.5 mg or 15 mg, lowest all-in cost with obesity-medicine physicians: Mochi Health.
• Price is the only constraint and you have a prescriber you trust: CoreAge RX.
• First-timer who wants a 10% weight loss guarantee: Shed.

Two providers we did not rank

Sprout Health. BBB F-rating. 2.2/5 Trustpilot from 12 reviews (84% one-star). Phone rings to voicemail with no callbacks. The “my account” page does not let you cancel despite the website’s claim. Customers report medication arriving ineffective.

TrimRx. BBB and Reddit document unexpected multi-month charges, difficulty canceling, and billing that continues after cancellation requests. Trustpilot is bimodal (57% 5-star, 29% 1-star), which usually signals a billing problem. Their flat-rate structure is attractive. Their retention practices are not.

When compounded stops making sense

Price-check LillyDirect before you commit. The Zepbound Self Pay Journey Program in April 2026 is $299 at 2.5 mg, $399 at 5 mg, and $449/month at 7.5 through 15 mg with a 45-day refill window. Miss the window and prices jump to $599 at 7.5 mg, up to $1,049 at 15 mg. At maintenance, LillyDirect at $449 is within $50 to $100 of several compounded providers. If legal certainty matters more than narrower savings, brand-name Zepbound is legitimate. Walmart pharmacy pickup (launched October 2025) makes it same-day.

Not sure where to start? Take the Peak Wellness intake for flat-rate injectable, the Eden intake for accreditation-first injectable, or the Henry Meds intake for oral or sublingual. All will tell you within one business day whether you qualify under the 2026 rules.

Still deciding between telehealth providers? Our best online tirzepatide guide covers the provider side in depth.

For the sister-category pharmacy comparison, see compounded semaglutide pharmacy comparison. For budget context, see tirzepatide cost without insurance.

FAQ

Is compounded tirzepatide still legal in 2026?

Yes, through a narrow 503A personalized-formulation pathway. The FDA declared the shortage resolved December 19, 2024, and 503A enforcement discretion ended February 18, 2025. Compounding is now permissible only for a documented individual medical need the FDA-approved product cannot meet: a polysorbate 80 allergy, a dose or route not commercially available, or a combination formulation with a clinically significant difference. Cost or convenience alone is prohibited as “essentially a copy.” Reference: FDA declaratory order.

What is the difference between 503A and 503B pharmacies for tirzepatide?

503A pharmacies are state-licensed and compound patient-specific prescriptions. 503B outsourcing facilities are FDA-registered, produce larger batches without individual prescriptions, and are subject to cGMP inspection. For tirzepatide, 503B compounding of standard copies ended March 19, 2025. 503A compounding remains permissible for documented personalization. Some 503B facilities (like Empower) operate through combination-formulation arguments under court injunctions.

What is a “documented medical need” for compounded tirzepatide?

Three recognized pathways. A documented allergy to polysorbate 80 (an excipient in Mounjaro and Zepbound that can cause type IV anaphylactoid reactions). A dose or route of administration not commercially available (microdose below 2.5 mg, oral or sublingual). A combination formulation with a clinically significant difference (tirzepatide plus niacinamide, plus B6, or plus glycine and B12). The prescription must document the rationale in writing.

Is compounded tirzepatide the same as Mounjaro or Zepbound?

Same active ingredient, not the same product. Compounded tirzepatide has not been reviewed by the FDA for safety, efficacy, or quality. It ships in multi-dose vials requiring syringe draw, not auto-injector pens. It may contain additives (niacinamide, B6, glycine) absent from brand-name products. Some compounders use tirzepatide sodium or acetate salt, which has different molecular weight and unknown bioequivalence to the free base used in SURMOUNT.

How much does compounded tirzepatide cost per month in 2026?

Range is $149 to $499/month. CoreAge RX is the lowest flat-rate at $149. Peak Wellness is $349 flat with a named pharmacy (Epiq Scripts). Mochi is $278 all-in ($199 medication plus $79 membership). Eden is $349 flat. MEDVi is $399 to $499. LillyDirect Zepbound (brand-name, FDA-approved) is $299 to $449/month through the Self Pay Journey Program with a 45-day refill window. At maintenance dose, that narrows the gap considerably.

Can I get compounded tirzepatide without a membership?

Yes. Peak Wellness ($349 flat), Eden ($349 flat), CoreAge RX ($149), Henry Meds ($199+), Shed ($299 to $399), and Sprout Health ($299) are no-membership providers. Mochi Health ($79/month) and Ro charge mandatory membership on top of medication cost. No membership is not no oversight. Every legitimate provider requires a licensed clinician consultation to write the prescription.

How do I verify a compounding pharmacy is legitimate (PCAB, NABP)?

Four verification tools. ACHC PCAB sterile compounding lookup at achc.org/find-a-provider/ (PCAB Sterile Compounding filter). NABP accreditation at nabp.pharmacy. 503B outsourcing registry at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. State pharmacy board license check. Request a Certificate of Analysis for your batch. Red flags: no COA, no physician consultation, pricing under $100/month.

What is compounded tirzepatide with B6 or niacinamide, and is it safer or more legitimate?

Combination formulations add pyridoxine (B6) at 50 mg/mL for nausea management or niacinamide at 2 mg/mL for formulation stability and metabolic support. The legal rationale: Mounjaro and Zepbound do not contain these additives, so compounded combinations arguably are not essentially copies. Clinical evidence is plausible but not RCT-validated against tirzepatide alone. Safer is unproven. More legally defensible is accurate versus straight tirzepatide compounds.

Can I switch providers without restarting my dose escalation?

Usually yes with documented dose history. Provide your new prescriber your current dose and weeks at that dose. Most providers continue you at your current dose rather than restart titration, provided tolerability has been established. Switching compounded to LillyDirect Zepbound matches directly (10 mg compounded to 10 mg Zepbound). Confirm the 45-day refill window for LillyDirect doses at 7.5 mg and above.

What are the real side effects I should expect?

SURMOUNT-1 data: nausea in 24% of patients (vs 9.5% placebo), vomiting 5.1% to 12.2% (dose-dependent), constipation and diarrhea common during titration. At 15 mg over 72 weeks, SURMOUNT-1 produced 22.5% mean body weight loss. AI analysis of 410,198 Reddit posts (Nature Health 2026): nausea 36.9%, fatigue 16.7%, vomiting 16.3%, constipation 15.3%, diarrhea 12.6%. Newly surfaced signals include menstrual irregularities in about 4% of users and temperature complaints. Most GI effects peak during dose escalation.